NeOnc Technologies Holdings, Inc. announced it will present clinical data from its intranasal NEO100 and oral NEO212 programs, both under development for central nervous system (CNS) cancers. The data will be shared via two poster presentations at the upcoming Society for Neuro-Oncology (SNO) annual meeting.
Key Details
- Event: 31st Annual Meeting of the Society for Neuro-Oncology (SNO) in Philadelphia, PA.
- Presentation Date: The two poster presentations are scheduled for November 13, 2026.
- NEO100 Program: Data will cover updated results from a Phase 1/2a study in recurrent astrocytoma, highlighting durable remission and prolonged survival.
- NEO212 Program: Data will include Phase 1 safety, pharmacokinetics (PK), and early signs of activity in patients with recurrent glioblastoma and brain metastases.